Loading stock data…
$6.04-0.06 (-0.98%)
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States.
Precision BioSciences, Inc. in the Healthcare sector is trading at $5.93 with a market capitalization of $200M. Wall Street consensus targets $29.40 (5 analysts), implying a +395.4% move over the next 12 months. The stock is currently 38% below its 52-week high of $9.62, remaining 7.1% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $10.84M↓ | $34.20M↑ | $13,000↓ | $18,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$19.16M↓ | -$9.07M↓ | $12.51M↑ | -$20.67M↑ | -$21.88M |
| Net Income | -$32.65M↓ | -$18.44M↓ | $20.13M↑ | -$21.77M↑ | -$23.52M |
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform ...